The dataset’s leading assignee holds 32 of the 106 records in scope, well ahead of the rest of the field. The top five assignees combined account for 70.8% of all 106 records, and the top ten reach 89.6%, meaning most of the documented claim space sits with a small group of university and research-institute filers rather than being spread across many commercial entrants. Anyone doing freedom-to-operate work in this space should look closely at that leading assignee’s claim family first.

Filing volume grew from 10 records in 2021 to 14 in 2024, a documented 40% increase over that span, and this is the most reliable read because 2024 is the last year that can be treated as largely complete. The years after that, including the apparent 2025 peak of 21 records, should not be read as either accelerating growth or a slowdown, because publication typically lags actual filing by around 18 months. The honest statement is that the field grew through 2024 and current-year figures are still filling in.

Claims cluster heavily around two IPC subclasses: C07K, covering peptides and proteins, appears on 51.9% of the 106 records, and G16B, covering bioinformatics methods, appears on 44.3%. A61K (medicinal preparations) and C12N (microorganisms and genetic engineering) follow at lower but still meaningful shares. Narrower classes like G16C (computational chemistry) and G06F (digital data processing) sit under 8%, indicating that claims framed purely around computational methods are comparatively rare compared to those pairing a molecule with a design process.